Veeda Clinical Research Limited

Are you looking to invest in a company that plays a critical role in the global drug development ecosystem? Veeda Clinical Research Limited is one of the largest independent full-service clinical research organizations (CROs) in India. Established in 2004, Veeda provides end-to-end clinical research solutions to pharmaceutical companies worldwide, helping them bring new drugs to market faster and more cost-effectively.

With a comprehensive service portfolio, state-of-the-art facilities, a growing global presence through strategic acquisitions, and a strong regulatory track record (85+ global regulatory inspections cleared), Veeda is well-positioned to capitalize on the booming global CRO market. The company filed its DRHP in 2021, making this a compelling pre-IPO investment opportunity.

1. Company Overview: A Leading Independent CRO Since 2004

• Established: 2004.

• Position: One of India’s largest independent, full-service clinical research organizations (CROs).

• Mission: To provide cost-effective and timely research solutions to pharmaceutical companies, aiding in the development and launch of new drugs.

• Global Reach: Has served clients in 27 countries , including major Indian and international pharmaceutical companies.

2. Business Model: End-to-End Clinical Research Solutions

Veeda operates on a comprehensive, integrated business model, offering a broad range of services across the entire drug development lifecycle.

Core Services Offered:

• Bioavailability & Bioequivalence (BA/BE) Studies: Specialized services to determine how a drug is absorbed and processed by the body. This is a core strength of Veeda.

• Pre-Clinical Trials: Research conducted before testing on humans, including animal studies.

• Clinical Trials (Phase I, II, III): Comprehensive services for all phases of human clinical trials.

• Bioanalytical Services: Advanced laboratory capabilities to analyze drug and metabolite levels in biological samples.

• Pharmacovigilance: Safety monitoring and regulatory compliance services to track and report adverse effects.

• Medical Writing: Preparation of essential study documents in compliance with global regulatory requirements.

3. Research Facilities: A Robust Infrastructure

Veeda has significantly expanded its infrastructure to support its growing operations.

4. Clientele: Serving Global and Indian Pharma Leaders

Veeda has built a strong reputation, serving clients in 27 countries .

Key Indian Clients:

• Dr. Reddy’s Laboratories

• Mankind Pharma

• Granules India

Key International Clients:

• Laboratorios Liconsa (Europe)

• Novugen Pharma (Malaysia)

• Upsher-Smith Laboratories (USA)

This diverse client base across geographies demonstrates Veeda’s credibility and global reach.

5. Strategic Acquisitions & Partnerships: Expanding Capabilities

Veeda has made strategic moves to strengthen its position and expand into high-growth segments.

A) Acquisition of Heads (European CRO)

• Target: Heads, a privately held European CRO specializing in oncology clinical trials .

• Established: 2010.

• Global Footprint: Operations in 25 strategic locations across Europe, North America, and the Asia Pacific.

• Strategic Rationale: This acquisition positions Veeda among the global CROs with integrated capabilities extending from discovery to clinical development and post-commercial launch. It adds specialized oncology expertise and a global footprint.

B) Acquisition of Bioneeds (Pre-Clinical Capabilities)

• Action: Acquired 50.10% stake in Bioneeds.

• Strategic Rationale: Enhanced Veeda’s pre-clinical capabilities, adding 99 exclusive experiment rooms in Bangalore.

C) Joint Venture with Somru BioScience (Ingenuity Biosciences)

• Action: Established Ingenuity Biosciences as a joint venture.

• Focus: To specialize in biosimilars , a high-growth segment in the pharmaceutical industry.

6. Regulatory Excellence: A Key Competitive Advantage

• 85+ Global Regulatory Inspections: Successfully completed inspections by stringent regulatory authorities, including the USFDA (United States Food and Drug Administration) and EMA (European Medicines Agency) .

• This track record is a powerful differentiator, as regulatory compliance is the most critical factor for pharmaceutical companies when selecting a CRO partner.

7. Industry Outlook: A Booming Global CRO Market

The global CRO market is projected to grow significantly, driven by:

• Increasing Pharmaceutical R&D Expenditures: Pharmaceutical companies are spending more on research and development.

• Outsourcing Trend: Pharma companies are increasingly outsourcing clinical research to specialized CROs to reduce costs, improve efficiency, and expedite drug development timelines.

• Complexity of Trials: The growing complexity of clinical trials (especially in areas like oncology and biosimilars) favors established CROs with specialized expertise like Veeda.

8. Recent Development: DRHP Filed in 2021

Veeda Clinical Research Limited filed its Draft Red Herring Prospectus (DRHP) in 2021 with the market regulator. The DRHP outlines the company’s business operations, financials, and strategic direction as part of its plan to go public. This is a major catalyst, signaling a potential IPO in the future.

Key Investment Highlights

1. Market Leadership: One of India’s largest independent full-service CROs, with a strong reputation and extensive experience.

2. End-to-End Service Offering: Comprehensive services covering pre-clinical, early phase, late phase, bioanalytical, pharmacovigilance, and medical writing.

3. Global Reach: Serves clients in 27 countries, including major Indian and international pharmaceutical companies.

4. Strategic Acquisitions: Acquisitions of Heads (oncology CRO) and Bioneeds (pre-clinical) have expanded capabilities and global footprint.

5. Strong Regulatory Track Record: Successfully cleared over 85 global regulatory inspections (USFDA, EMA), a critical competitive advantage.

6. Robust Infrastructure: Significant clinical and pre-clinical facilities with 532 beds in Ahmedabad and 99 pre-clinical rooms in Bangalore.

7. Beneficiary of Industry Trends: Well-positioned to capitalize on the global outsourcing trend and growth in pharmaceutical R&D spending.

8. Pre-IPO Opportunity: Filed DRHP in 2021, indicating a potential IPO and future liquidity event.

Risks to Consider

1. Intense Competition: The CRO industry is highly competitive, with numerous global and domestic players.

2. Regulatory Risks: The business is heavily dependent on maintaining a flawless regulatory record. Any major non-compliance could be catastrophic.

3. Client Concentration Risk: A significant portion of revenue may come from a few large clients. Loss of a major client could impact revenue.

4. Pricing Pressure: Pharma companies are increasingly cost-conscious, which could put pressure on pricing.

5. Dependence on Skilled Talent: The business relies on highly skilled scientists, clinicians, and project managers. Attracting and retaining talent is critical.

6. Integration Risk: Successfully integrating acquired entities (Heads, Bioneeds) and realizing synergies is a significant operational challenge.

7. IPO Timing Uncertainty: While the DRHP was filed in 2021, the actual timing of the IPO remains uncertain and depends on market conditions.

8. Unlisted Liquidity: As an unlisted company, shares are not traded on public exchanges, and liquidity may be limited until the IPO.

Valuation & Unlisted Share Price

(Note: The source text did not provide a specific current valuation or share price. Investors should check the Unlisted Network platform for the latest traded price.)

• Outstanding Shares: Information not provided.

• Share Price: Please check the Unlisted Network Android or iOS mobile app for the latest traded price and historical data.

The Opportunity: Own a Stake in a Pre-IPO Clinical Research Leader

Veeda Clinical Research offers a unique opportunity to invest in a company at the forefront of the global drug development ecosystem. With its comprehensive service portfolio, strategic acquisitions, exceptional regulatory track record, and filed DRHP, Veeda is poised for significant growth. For investors seeking exposure to the high-growth pharmaceutical services sector, Veeda is a compelling pre-IPO addition to a diversified portfolio.

Ready to Add a Pre-IPO Clinical Research Leader to Your Portfolio?

Buy Unlisted Shares of Veeda Clinical Research Ltd exclusively through Unlisted Network.

Invest in the company helping bring new medicines to the world.